55.65MMarket Cap-8000P/E (TTM)
3.7200High3.4200Low113.22KVolume3.5800Open3.5600Pre Close404.89KTurnover0.89%Turnover RatioLossP/E (Static)15.81MShares6.850052wk High5.50P/B44.97MFloat Cap0.850052wk Low--Dividend TTM12.78MShs Float12.5000Historical High--Div YieldTTM8.43%Amplitude0.6488Historical Low3.5760Avg Price1Lot Size
Lexaria Bioscience Stock Forum
Lexaria's Second GLP-1 Human Pilot Study Shows Zero Adverse Events in DehydraTECH-processed Rybelsus(R) Oral Capsules
Lexaria Bioscience Corp. (NASDAQ:LEXX) has announced positive results from its second GLP-1 human pilot study (GLP-1-H24-2) on DehydraTECH-processed Rybelsus® oral capsules. Key findings include:
1. Superior tolerability: None of the 9 participants taking DehydraTECH-processed Rybelsus® capsules experienced adverse events, compared...
Larger Image: tradingview.com...
$Lexaria Bioscience (LEXX.US)$
MT Newswires· 1 min ago
Lexaria Bioscience: Dehydratech-Processed Rybelsus Evidenced Trend Toward Higher Overall Absorption Vs Rybelsus Not Processed With Dehydratech
Lexaria Bioscience Corp. (Nasdaq:LEXX, LEXXW), a global innovator in drug delivery platforms, recently announced interim results from the first four weeks of dosing in its ongoing diabetes animal study, WEIGHT-A24-1 (the "Study"). $Lexaria Bioscience (LEXX.US)$
https://stockregion.app/p/bioscience-company-reports-positive-6c7
Positive Interim Body Weight Results from Lexaria's Diabetes Animal Study
Lexaria Bioscience Corp. (Nasdaq: LEXX) reports positive interim results from its diabetes animal study WEIGHT-A24-1. After 28 days of dosing, DehydraTECH-processed drug therapies showed decreased body weight gain or weight reduction. Key findings include:
1. DehydraTECH-CBD formulation 3 and DehydraTECH-liraglutide produced the largest weight loss: -1.50% and -1.58% respectively.
2. De...
Accesswire· 3 mins ago
No comment yet